CLL14
One year of two targeted drugs, then nothing: more than half of patients were still progression-free six years later, off all treatment.
Median PFS 76.2 vs 36.4 months (HR 0.40); 6-year PFS 53.1% vs 21.7%; time to next treatment 65.2% vs 37.1% at 6 years; uMRD at end of treatment 75.5% vs 35.2%; OS not significantly different. NEJM 2019; Blood 2024 (6-year). Established fixed-duration therapy as a CLL standard and uMRD as a predictor of durable remission.
- Median 76.2 vs 36.4 months with Venetoclax + obinutuzumab compared with Chlorambucil + obinutuzumab; about 39.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 60 percent lower chance of the event at any given time (hazard ratio 0.4).
- The p-value (<0.0001) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- 53.1 vs 21.7 out of 100 alive without the cancer growing at 6 years with Venetoclax + obinutuzumab compared with Chlorambucil + obinutuzumab; 31.4 more per 100.
- Roughly one extra person helped for every 3 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- 75.5 vs 35.2 out of 100 had no detectable disease on sensitive tests with Venetoclax + obinutuzumab compared with Chlorambucil + obinutuzumab; 40.3 more per 100.
- Roughly one extra person helped for every 2 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Previously untreated CLL with coexisting conditions: 12 months of venetoclax + obinutuzumab vs chlorambucil + obinutuzumab. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
432 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (median)primary | Venetoclax + obinutuzumab | 216 | 76.2 months | 0.4 | <0.0001 | link |
| Chlorambucil + obinutuzumab | 216 | 36.4 months | ||||
| Progression-free survival at 6 years | Venetoclax + obinutuzumab | — | 53.1% | — | — | — |
| Chlorambucil + obinutuzumab | — | 21.7% | ||||
| Undetectable MRD in blood at end of treatment | Venetoclax + obinutuzumab | — | 75.5% | — | — | — |
| Chlorambucil + obinutuzumab | — | 35.2% |
Pages like this
not linked directly; found by shared links- TrialCLL13 / GAIA
Shares Venetoclax + obinutuzumab (12 months), Michael Hallek, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Obinutuzumab.
- TrialAMPLIFY
Shares Obinutuzumab, CD20, BCL-2, Venetoclax.
- TrialGLOW
Shares Obinutuzumab, BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- TrialVIALE-A
Shares Tumour lysis syndrome (TLS), BCL-2, Venetoclax, Older and multimorbid patients are excluded and undertreated.
- TrialCAPTIVATE
Shares MRD-negative complete remission, BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- Key paperMURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL
Shares CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, CD20, BCL-2, Venetoclax.
- TrialCELESTIAL-TNCLL
Shares Obinutuzumab, BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- TrialELEVATE-TN
Shares Obinutuzumab, CD20, Chronic lymphocytic leukaemia.